Date:
July 26, 2021
Issue #:
1629
Summary:
The interleukin-6 (IL-6) receptor antagonist
tocilizumab (Actemra – Genentech) has received an
Emergency Use Authorization (EUA) from the FDA for
IV treatment of COVID-19 in hospitalized patients ≥2
years old who are receiving a systemic corticosteroid
and require supplemental oxygen, mechanical
ventilation, or extracorporeal membrane oxygenation
(ECMO). Tocilizumab has been approved by the FDA
for various indications, including rheumatoid arthritis
and juvenile idiopathic arthritis.
tocilizumab (Actemra – Genentech) has received an
Emergency Use Authorization (EUA) from the FDA for
IV treatment of COVID-19 in hospitalized patients ≥2
years old who are receiving a systemic corticosteroid
and require supplemental oxygen, mechanical
ventilation, or extracorporeal membrane oxygenation
(ECMO). Tocilizumab has been approved by the FDA
for various indications, including rheumatoid arthritis
and juvenile idiopathic arthritis.
